Phesi launches self-service Investigator Site Profiler solution to enhance precision of investigator site selection
Solution benefits clinical development and medical affairs groups – eliminating 20%-30% of investigator sites where there isn’t sufficient data to ensure performance
Boston, US. 2nd April 2025. Phesi, a global provider of patient-centric data analytics has launched its self-service Investigator Site Profiler solution. Leveraging the data lake from Phesi’s award-winning AI-powered Trial Accelerator™ platform, including dynamically updated records from 600,000 investigator sites in 195 countries across 4,000+ indications, Investigator Site Profiler enables heads of feasibility, medical monitors and study managers to eliminate 20-30% of sites from investigator site lists. Investigator Site Profiler transforms strategic and operational feasibility and enables faster enrolment to substantially reduce the cost of investigator site activation and monitoring processes.
“Investigator Site Profiler democratizes access to industry data and brings transparency and objectivity into the investigator site selection process,” commented Dr Gen Li, Founder and CEO, Phesi. “Too often, investigator site selection is based on previous experience, proximity to a location, or simple lists of ‘top-tier’ sites – rather than detailed and objective data analysis. Investigator Site Profiler changes this by dynamically analyzing nominations against various protocol specific elements, including investigator medical expertise, trial design, comparator and treatment modality, among others, from the world’s largest contextualized data repository. Simply put, Investigator Site Profiler allows sponsors to find the ‘needles in the haystack’ – the specific investigator sites best suited for their particular trial.”
Investigator Site Profiler has an established and successful track-record, having been used by Phesi as part of its data science and feasibility business for the last 20 years to support the commercialization of many high-profile, innovative life saving therapies. Now transitioned to be made available via a licensable model, even more users in clinical development and medical affairs can benefit from Investigator Site Profiler’s proven ability to accurately and consistently predict investigator site enrollment performance. As a self-service SaaS solution, Investigator Site Profiler makes the award-winning platform accessible to teams of all sizes – from start-ups to global organizations.
Serving as a vital quality assurance step to investigator site nominations by internal medical and study teams, CROs, or existing third-party feasibility tools, users of Investigator Site Profiler can confidently and precisely confirm the accuracy of a proposed list and predict and remove poorly performing investigator sites. With an automated batch loading capacity, users can check the quality of thousands of nominated sites rapidly. The solution can be used as a standalone platform, or in conjunction with Phesi’s AI-powered Trial Accelerator platform.
“Investigator Site Profiler works in concert with other Phesi solutions and services like Digital Patient Profiling and the Patient Access Score (PAS) to further enhance the design and execution of clinical development programmes,” commented Jonathan Peachey, COO, Phesi. “We have been delighted by the reception to Investigator Site Profiler and are excited to be putting the solution into more people’s hands. Given an investigator site on average costs $50,000 to activate and $5,000 per month to manage, Investigator Site Profiler can easily deliver significant return on investment for sponsors.”
The self-service Investigator Site Profiler is available for users to license now.
Visit https://info.phesi.com/investigator-site-profiler for an interactive demo and contact info@phesi.com for further information.
To book a meeting at CMOS 2025 (booth #21), visit: https://info.phesi.com/cmos-2025
